Who is sponsoring NCT01341808?

NCT01341808 is sponsored by Asan Medical Center.

What drugs are being tested in NCT01341808?

Interventions in NCT01341808: Epaxal Berna (virosomal hepatitis A vaccine).

What condition does NCT01341808 study?

NCT01341808 studies Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis, Hepatitis A.

Is NCT01341808 still recruiting?

NCT01341808 is currently completed. Last updated 16 March 2013.

Last reviewed 2013-03-16 · How we verify

NCT01341808

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Immunogenicity of Hepatitis A Vaccine in Patients With Inflammatory Bowel Disease

Completed Phase 4 Last updated 16 March 2013

What this trial tests

Phase 4 trial testing Epaxal Berna (virosomal hepatitis A vaccine) in Inflammatory Bowel Disease in 493 participants. Completed in 1 March 2013.

Timeline

1 April 2011

Primary endpoint
1 February 2013

1 March 2013

Quick facts

Lead sponsor	Asan Medical Center
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	prevention
Enrollment	493
Start date	1 April 2011
Primary completion	1 February 2013
Estimated completion	1 March 2013
Sites	1 location across South Korea

Drugs / interventions tested

Epaxal Berna (virosomal hepatitis A vaccine) — full drug profile →

Conditions studied

Inflammatory Bowel Disease — all drugs for Inflammatory Bowel Disease →
Crohn's Disease — all drugs for Crohn's Disease →
Ulcerative Colitis — all drugs for Ulcerative Colitis →
Hepatitis A — all drugs for Hepatitis A →

Sponsor

Asan Medical Center

Who can join

Adults 18 to 40, any sex, with Inflammatory Bowel Disease or Crohn's Disease. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

antibody titer to hepatitis A vaccine
Time frame: Month 7

Sponsor's own description

The purpose of this study is to measure the immune response in 18-40 year old IBD patients after receiving the hepatitis A vaccine.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Immunomodulatory Nanosystems.
Feng X, Xu W, Li Z, Song W, et al · · 2019 · cited 252× · PMID 31508270 · DOI 10.1002/advs.201900101
Efficacy of hepatitis A vaccination and factors impacting on seroconversion in patients with inflammatory bowel disease.
Park SH, Yang SK, Park SK, Kim JW, et al · · 2014 · cited 57× · PMID 24284413 · DOI 10.1097/01.mib.0000437736.91712.a1

Verify or expand the search:

Other recruiting trials for Inflammatory Bowel Disease

Currently open trials in the same condition.

NCT07210580 — Testing the Impact of Measurement-Based Care on Quality of Life and Disease Management Among Veterans With Inflammatory · NA · recruiting
NCT07242248 — A Study to Observe Real-world Evidence of Guselkumab Treatment in Participants With Ulcerative Colitis and Crohn's Disea · recruiting
NCT07102368 — A Study to Generate Real-world Evidence of Guselkumab Effectiveness in Inflammatory Bowel Disease in Germany · recruiting
NCT07252427 — Gut Microbiota in IBD With Comorbid Depressive Disorder · recruiting
NCT06781827 — Research on the Use of Probiotics in the Prevention and Treatment of Inflammatory Bowel Disease · NA · recruiting

Other Asan Medical Center trials

Trials by the same sponsor.

NCT07530393 — Blood Viscosity and Outcomes After Elective Craniotomy · not yet recruiting
NCT07010497 — A Prospective Study to Evaluate the Safety and Efficacy of the Combination Therapy of Irpagratinib, Atezolizumab, and Be · Phase 2 · recruiting
NCT07382505 — Prospective Cohort Study of Minimal Residual Disease(MRD) Testing for Early Recurrence Detection in Endometrial and Cerv · not yet recruiting
NCT07489092 — Feasibility of a Digital Rehabilitation Platform in Patients After ICU Discharge · NA · recruiting
NCT07431762 — Comparison of Anti-Thrombotic Treatments Between Aspirin and Warfarin During Initial Six Months After Bioprpsthetic Hear · Phase 4 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01341808 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Asan Medical Center
Last refreshed: 16 March 2013

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01341808.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing